Assessing Response and Loss of Response to Biological Therapies in IBD
- 1 April 2011
- journal article
- case report
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Gastroenterology
- Vol. 106 (4), 685-698
- https://doi.org/10.1038/ajg.2011.103
Abstract
The American Journal of Gastroenterology is published by Nature Publishing Group (NPG) on behalf of the American College of Gastroenterology (ACG). Ranked the #1 clinical journal covering gastroenterology and hepatology*, The American Journal of Gastroenterology (AJG) provides practical and professional support for clinicians dealing with the gastroenterological disorders seen most often in patients. Published with practicing clinicians in mind, the journal aims to be easily accessible, organizing its content by topic, both online and in print. www.amjgastro.com, *2007 Journal Citation Report (Thomson Reuters, 2008)Keywords
This publication has 96 references indexed in Scilit:
- Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-AnalysisClinical Gastroenterology and Hepatology, 2009
- Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?Annals Of The Rheumatic Diseases, 2009
- Adalimumab for the treatment of fistulas in patients with Crohn's diseaseGut, 2009
- Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-α antibodiesClinical and Experimental Immunology, 2008
- An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody statusClinical Rheumatology, 2008
- TNFα blockade in human diseases: Mechanisms and future directionsClinical Immunology, 2008
- Unravelling the pathogenesis of inflammatory bowel diseaseNature, 2007
- Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trialGut, 2007
- Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's diseaseGut, 2007
- Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2007